- Home
- GRVY vs PROK Comparison
GRVY vs PROK Comparison
Compare GRVY & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRVY
- PROK
- Stock Information
- Founded
- GRVY 2000
- PROK 2015
- Country
- GRVY South Korea
- PROK United States
- Employees
- GRVY N/A
- PROK N/A
- Industry
- GRVY Business Services
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GRVY Consumer Discretionary
- PROK Health Care
- Exchange
- GRVY Nasdaq
- PROK Nasdaq
- Market Cap
- GRVY 412.9M
- PROK 417.1M
- IPO Year
- GRVY 2005
- PROK N/A
- Fundamental
- Price
- GRVY $59.51
- PROK $2.43
- Analyst Decision
- GRVY
- PROK Strong Buy
- Analyst Count
- GRVY 0
- PROK 4
- Target Price
- GRVY N/A
- PROK $6.25
- AVG Volume (30 Days)
- GRVY 13.1K
- PROK 1.7M
- Earning Date
- GRVY 11-07-2025
- PROK 11-10-2025
- Dividend Yield
- GRVY N/A
- PROK N/A
- EPS Growth
- GRVY N/A
- PROK N/A
- EPS
- GRVY 8.02
- PROK N/A
- Revenue
- GRVY $399,496,744.00
- PROK $744,000.00
- Revenue This Year
- GRVY N/A
- PROK $471.74
- Revenue Next Year
- GRVY N/A
- PROK N/A
- P/E Ratio
- GRVY $7.25
- PROK N/A
- Revenue Growth
- GRVY 12.13
- PROK N/A
- 52 Week Low
- GRVY $53.12
- PROK $0.46
- 52 Week High
- GRVY $70.00
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- GRVY 41.86
- PROK 37.96
- Support Level
- GRVY $57.04
- PROK $2.56
- Resistance Level
- GRVY $60.50
- PROK $2.88
- Average True Range (ATR)
- GRVY 1.36
- PROK 0.25
- MACD
- GRVY 0.22
- PROK -0.08
- Stochastic Oscillator
- GRVY 39.17
- PROK 19.34
About GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.